Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1946-100free.
--
Merck & Co., Inc. Analyst Notes
On April 29, 2014, Merck & Co., Inc. (Merck) reported Q1 2014 financial results. During the quarter, the Company's worldwide sales declined 3.8% YoY to $10.3 billion, which reflected unfavourable impact of patent expiries and a 2% unfavourable impact from foreign exchange. Q1 2014 GAAP net income was $1.7 billion, or $0.57 per diluted share, compared to $1.6 billion, or $0.52 per diluted share, in Q1 2013. Further, quarterly non-GAAP net income came in at $2.60 billion, or $0.88 per diluted share, compared to $2.59 billion, or $0.85 per diluted share, in Q1 2013. For full year 2014, Merck expects non-GAAP EPS to be between $3.35 to $3.53 and GAAP EPS in the range of $2.15 to $2.47. Full-year 2014 revenues are expected to be between $42.4 billion and $43.2 billion. The full analyst notes on Merck are available to download free of charge at:
http://www.analystsreview.com/1946-MRK-02May2014.pdf
--
Johnson & Johnson Analyst Notes
On April 25, 2014, Johnson & Johnson's subsidiary Janssen-Cilag International IV (Janssen) announced that it has received European Commission's (EC) approval for VOKANAMET in European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. The Company notified that the EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending the approval of canagliflozin and immediate release metformin hydrochloride fixed dose combination therapy, in February 2014. The full analyst notes on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/1946-JNJ-02May2014.pdf
--
Bristol-Myers Squibb Company Analyst Notes
On April 29, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) reported Q1 2014 financial results. In Q1 2014, the Company declared total revenues of $3.8 billion, down 0.5% YoY. Quarterly net earnings attributable to Bristol-Myers Squibb were $937 million, or $0.56 per diluted share, compared to $609 million, or $0.37 per diluted share, in Q1 2013. For full year 2014, Bristol-Myers Squibb expects revenues to be between $15.2 billion and $15.8 billion, and both GAAP and non-GAAP EPS to range between $1.70 and $1.80. The full analyst notes on Bristol-Myers Squibb are available to download free of charge at:
http://www.analystsreview.com/1946-BMY-02May2014.pdf
--
Teva Pharmaceutical Industries Ltd. Analyst Notes
On April 29, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced that the European Commission (EC) has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. "This is a major advance in inhalers - the need for more intuitive devices is critical and has been highlighted by healthcare professionals and patient groups. It is widely accepted that poor or inadequate inhaler technique not only negatively impacts treatment adherence, but means that patients do not obtain the full benefit from their medication," said Rob Koremans, M.D., President and CEO of Teva Global Specialty Medicines. The full analyst notes on Teva are available to download free of charge at:
http://www.analystsreview.com/1946-TEVA-02May2014.pdf
--
AbbVie Inc. Analyst Notes
On April 25, 2014, AbbVie Inc. (AbbVie) reported Q1 2014 financial results. In Q1 2014, the Company's sales were up 5.4% YoY to $4.6 billion, driven by the continued strength of HUMIRA. Net earnings for the quarter came in at $980 million, or $0.61 per diluted share, compared to $968 million, or $0.68 per diluted share, in Q1 2013. For full year 2014, AbbVie expects diluted EPS to be between $3.00 and $3.10 on an adjusted basis, and $2.63 to $2.73 on a GAAP basis. Full-year 2014 revenues are expected at c. $19 billion. The full analyst notes on AbbVie are available to download free of charge at:
http://www.analystsreview.com/1946-ABBV-02May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review